An Open-Label Study to Assess the Safety and Tolerability of Active Immunotherapy With Escalating Doses of OBI-833/OBI-821 (Globo H-CRM197/OBI-821) in Subjects With Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2016
At a glance
- Drugs OBI 833 (Primary)
- Indications Breast cancer; Colorectal cancer; Gastric cancer; Lung cancer
- Focus Adverse reactions; First in man
- Sponsors OBI Pharma
- 29 Nov 2016 Planned number of patients changed from 26 to 58.
- 09 Sep 2016 Planned End Date changed from 1 Nov 2017 to 1 Dec 2018.
- 09 Sep 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2017.